相关临床试验
44
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1911
已完成
22
50.0%
终止
1
2.3%
Unknown
20
45.5%
撤回
1
2.3%
暂无批准数据
- Sildenafil, the active ingredient in Viagra, interferes with cancer cells' ability to metastasize by blocking cholesterol access, according to new research from the Weizmann Institute of Science. - The drug traps cholesterol inside cancer cells' recycling compartments, depriving tumors of a critical building block needed for membrane reorganization during invasion and spread. - An observational analysis of 40,000 male cancer patients found those who used sildenafil before diagnosis had better overall survival, with an even stronger association when combined with statins. - Researchers emphasize these findings are preclinical and require clinical trials before sildenafil can be considered for cancer treatment; patients should not self-medicate.
- The Israel Medical Association published a position paper establishing principles for integrating AI into clinical settings, emphasizing that AI systems must support rather than replace physician decision-making. - The American Medical Association adopted new policies calling for mandatory physician oversight, transparency, and accountability whenever AI is used in patient care or health insurance decisions. - Both organizations warn that AI risks include biased training data, false sense of security, hallucinations, and the erosion of the doctor-patient relationship if human context is sidelined. - The AMA is advocating for regular audits of AI-driven clinical review tools and full disclosure when AI influences prior authorization or coverage determinations.
- Israeli medical device company Pulsenmore has received FDA marketing approval for its at-home ultrasound device, marking the first time such approval has been granted for an ultrasound device intended for home use by pregnant women. - The Pulsenmore ES device allows expectant mothers to perform ultrasound scans at home either through a smartphone-connected cradle or under remote medical professional guidance via telemedicine. - The FDA approval follows the rigorous 510k de novo pathway, establishing Pulsenmore as the predicate device for future competitors in this new product category. - With approximately 3.6 million births occurring annually in the United States, the device addresses critical access issues in prenatal care, particularly for women in remote areas or those requiring frequent high-risk pregnancy monitoring.
- Research presented at the European Congress on Obesity suggests weight loss injections may reduce obesity-related cancer risk by nearly 50%, potentially through anti-inflammatory mechanisms beyond simple weight reduction. - Scientists from the University of Manchester are designing a large-scale clinical trial involving tens of thousands of patients to further investigate GLP-1 agonists as cancer prevention tools. - Experts believe these findings could herald a "new dawn" in preventative cancer medicine, potentially benefiting even non-obese individuals with high cancer risk factors.
- IR-MED's PressureSafe device demonstrated 89% sensitivity and 90% specificity in Israeli clinical studies, with no adverse events across 1,475 scans for pressure injury assessment. - The company is expanding its AI-driven spectroscopy platform with DiaSafe, a new device for diabetic foot ulcer assessment, backed by a $1 million budget with 50% grant funding from Israel Innovation Authority. - IR-MED is accelerating U.S. usability studies following positive reception at the National Pressure Injury Advisory Panel Conference, while simultaneously pursuing Nasdaq uplisting to enhance shareholder value.
- Multiple large-scale real-world studies consistently demonstrate that apixaban is associated with 31-45% lower risk of major bleeding events compared to rivaroxaban in patients with non-valvular atrial fibrillation. - The COBRA-AF study, analyzing 177,866 propensity-matched patient pairs, found apixaban reduced the composite risk of major and clinically relevant non-major bleeding by 31% versus rivaroxaban. - Apixaban showed superior safety profiles across diverse patient populations, including those with chronic liver disease and bleeding history, while maintaining comparable stroke prevention efficacy.
